natgillin/translations-raw huggingface dataset:
ª If Dose Limiting Toxicity (DLT) occurs on &gt; Day15 of a cycle, lenalidomide dosing will be interrupted for at least the remainder of the current 28- day cycle.
ª Če toksičnost, ki omejuje odmerek (DLT - Dose Limiting Toxicity), nastopi po 15. dnevu cikla, prekinite zdravljenje z lenalidomidom vsaj za preostanek trenutnega 28-dnevnega cikla.
ª If Dose Limiting Toxicity (DLT) occurs on &gt; Day15 of a cycle, lenalidomide dosing will be interrupted for at least the remainder of the current 28-day cycle.
ª Če toksičnost, ki omejuje odmerek (DLT - Dose Limiting Toxicity), nastopi po 15. dnevu cikla, prekinite zdravljenje z lenalidomidom vsaj za preostanek trenutnega 28-dnevnega cikla.
° Significantly associated with Betaferon treatment for SPMS, p &lt; 0.05
° statistično značilno povezano z uporabo zdravila Betaferon pri SP-MS, p &lt; 0,05
° Significantly associated with Extavia treatment for SPMS, p &lt; 0.05
° statistično značilno povezano z uporabo zdravila Extavia pri SPMS, p &lt; 0,05
¶ Clinical efficacy was also observed ( &lt; 5 patients) in the following Candida species: C. guilliermondii, C. famata, C. lusitaniae, C. utilis, C. inconspicua and C. dubliniensis.
¶ Klinično učinkovitost so opazili ( &lt; 5 bolnikov) tudi pri naslednjih sevih Candide: C. guilliermondii, C. famata, C. lusitaniae, C. utilis, C. inconspicua in C. dubliniensis.
¶p-value &lt; 0.001.
¶vrednost p &lt; 0,001
β2M &gt; 3500 μg/l (n=322)
β2M &gt; 3.500 μg/l (n = 322)
Бьорингер Ингелхайм РЦВ ГмбХ и Ко КГ - клон България
Boehringer Ingelheim RCV GmbH &amp; Co KG Lietuvos filialas
↑ Indicates increase, ↓ indicates decrease, ↔ indicates minimal change ( &lt; 10 %)
↑ kaže povečanje, ↓ kaže zmanjšanje, ↔ kaže minimalno razliko ( &lt; 10 %)
≤ 0.125 mg/l; Resistant &gt; 0.125 mg/l.
≤ 0,125 mg/l; odporni &gt; 0,125 mg/l.
≤ 25,000/l during the study, including 14% &lt; 10,000/l; in contrast, with a baseline platelet count
&lt; 75.000/l, je med preskušanjem imelo število trombocitov ≤ 25.000/l (vključno s 14% bolnikov, ki so imeli število trombocitov &lt; 10.000/l).
≤ 400,000 copies/mL, or &gt; 400,000 copies/mL), by CD4+ cell count ( &lt; 50 cells/µL, 50-199 cells/µL, or ≥ 200 cells/µL), and by region (US or ex US).
&gt; 100.000 kopij/ml do ≤ 400.000 kopij/ml ali &gt; 400.000 kopij/ml), po številu celic CD4+ ( &lt; 50 celic/μl, 50–199 celic/μl ali ≥ 200 celic/μl) in po regiji (ZDA ali zunaj ZDA).
≤ 400,000 copies/mL, or &gt; 400,000 copies/mL), by CD4+ cell count ( &lt; 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US).
&gt; 100.000 kopij/ml do ≤ 400.000 kopij/ml ali &gt; 400.000 kopij/ml), po številu celic CD4+ ( &lt; 50 celic/μl, 50-199 celic/μl ali ≥ 200 celic/μl) in po regiji (ZDA ali zunaj ZDA).
≤ 400,000 copies/mL, or &gt; 400,000 copies/mL), by CD4+ cell count ( &lt; 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US).
&gt; 100.000 kopij/ml do ≤ 400.000 kopij/ml ali &gt; 400.000 kopij/ml), po številu celic CD4+ ( &lt; 50 celic/μl, 50–199 celic/μl ali ≥ 200 celic/μl) in po regiji (ZDA ali zunaj ZDA).
≤ 50 ml/min) or with moderate to severe hepatic impairment (Child-Pugh score &gt; 6) (see sections 4.3, 4.4 and 5.2).
≤ 50 ml/min) ali z zmerno do hudo okvarjenim delovanjem jeter (število točk po Child-Pughu ≥ 6) kontraindiciran (glejte poglavja 4.3, 4.4 in 5.2).
≤ Grade 1 ( &lt; 1.5 x IULN) Recurrence at 15 mg:
≤ 1. stopnjo ( &lt; 1,5 x IULN) začnite z odmerkom 15 mg Ponovni pojavi pri 15 mg:
≤ Grade 1 ( &lt; 1.5 x IULN) Recurrence at 15 mg:
≤ 1. stopnjo( &lt; 1,5 x IULN) začnite z odmerkom 15 mg Ponovni pojavi pri 15 mg:
≤ Grade 1 ( &lt; 1.5 x IULN) Recurrence at 30 mg:
≤ 1. stopnjo ( &lt; 1,5 x IULN) začnite z odmerkom 30 mg Ponovni pojav pri 30 mg:
≤10 ml or 20 ml syringe for administration of volumes of &gt; 10 ml)
≤ 10 ml ali 20 ml brizga za odmerjanje količin &gt; 10 ml)
≥ 0.5 and &lt; 1.5 x 109/l
≥ 0,5 in &lt; 1,5 x 109/l
≥ 0.5 and &lt; 1.5 x 109/l
 0,5 in &lt; 1,5 x 109/l
≥ 0.5 to &lt; 0.8
≥ 0,5 do &lt; 0,8
≥ 0.5 to &lt; 0.9
≥ 0,5 do &lt; 0,9
≥ 0.5 x 109/l, and &lt; 0.75 x 109/l
≥ 0,5 x 109/l in &lt; 0,75 x 109/l
≥ 0.8 to &lt; 1.2
≥ 0,8 do &lt; 1,2
≥ 0.9 to &lt; 1.4
≥ 0,9 do &lt; 1,4
≥ 1.2 to &lt; 1.4
≥ 1,2 do &lt; 1,4
≥ 1/1,000 to &lt; 1/100
≥ 1/1.000 do &lt; 1/100
≥ 1/1,000 to &lt; 1/100, rare ≥1/10,000 to &lt; 1/1,000, very rare &lt; 1/10,000).
&lt; 1/10, občasni ≥1/1.000 do &lt; 1/100, redki ≥1/10.000 do &lt; 1/1.000, zelo redki &lt; 1/10.000).
≥ 1/10,000 to &lt; 1/1000
≥ 1/10.000 do &lt; 1/1.000
≥ 10 and &lt; 100 x 109/l
≥ 10 in &lt; 100 x 109/l
≥ 10 and &lt; 100 x 109/l
 10 in &lt; 100 x 109/l
≥ 100,000 copies/ml or CD4+ cell count &lt; 100 cells x 106/l (see section 4.2 and 4.4).
&lt; 100 celic x 106/l (glejte poglavji 4.2 in 4.4).
≥ 12 to &lt; 18 years, n (%)
≥ 12 do &lt; 18 let, n (%)
≥ 12 years to &lt; 18 years and 12 mg/kg* Every 8 hours 60 bodyweight &lt; 33 kg
≥ 12 let do &lt; 18 let in s telesno 12 mg/kg* na 8 ur 60 maso &lt; 33 kg
≥ 2 months to &lt; 2 years 8 mg/kg Every 8 hours 60
≥ 2 meseca do &lt; 2 leti 8 mg/kg na 8 ur 60
≥ 2 years to &lt; 12 years
≥ 2 leti do &lt; 12 let
≥ 2 years to &lt; 12 years 12 mg/kg* Every 8 hours 60
≥ 2 leti do &lt; 12 let 12 mg/kg* na 8 ur 60
≥ 20 and &lt; 30 (n=18)
≥ 20 in &lt; 30 (n=18)
≥ 200 and &lt; 350
≥ 200 in &lt; 350
≥ 25 x 109/l, and &lt; 50 x 109/l
≥ 25 x 109/l in &lt; 50 x 109/l
≥ 27 kg/m2 to &lt; 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)
≥27 kg/m2 do ≤30 kg/m2 (bolniki s čezmerno telesno maso) z enim ali več spremljajočimi dejavniki tveganja (npr. sladkorna bolezen tipa 2, dislipidemija ali nadzorovana hipertenzija).
≥ 30 and &lt; 40 (n=9)
≥ 30 in &lt; 40 (n=9)
≥ 30,000 and &lt; 100,000 copies/ml
≥ 30.000 in &lt; 100.000 kopij/ml
≥ 325 metres, the treatment effect was 38.4 metres in favour of sildenafil; for patients with a baseline walking distance &lt; 325 metres, the treatment effect was 2.3 metres in favour of placebo.
Pri bolnikih z izhodiščno prehojeno razdaljo ≥ 325 metrov je bil učinek zdravljenja 38,4 metra v korist sildenafila; pri bolnikih z izhodiščno prehojeno razdaljo &lt; 325 metrov je bil učinek zdravljenja 2,3 metra v korist placeba.
≥ 3x ULN ALT with simultaneous elevation of bilirubin concentration &gt; 2x ULN
≥ 3 x ULN ALT s hkratnim zvišanjem koncentracije bilirubina &gt; 2 x ULN.
≥ 4.5 mg/dl for patients with TIH and ≥ 265 μmol/l or ≥ 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance &lt; 30 ml/min), the use of zoledronic acid is not recommended in patients with severe renal impairment.
TIH - oziroma z vrednostmi serumskega kreatinina ≥ 265 µmol/l ali ≥ 3,0 mg/dl za bolnike z rakom in zasevki v kosteh) in glede na samo omejene farmakokinetične podatke pri bolnikih s hudo izhodiščno okvaro ledvic (očistek kreatinina &lt; 30 ml/min), se uporabe zdravila Zoledronska kislina Mylan pri bolnikih s hudo okvaro ledvic ne priporoča.
≥ 40 and &lt; 50 (n=5)
≥ 40 in &lt; 50 (n=5)
≥ 50 and &lt; 200
≥ 50 in &lt; 200
≥ 50,000 but &lt; 75,000
≥ 50.000 ali
≥ 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF &lt; 500 msec) were uncommon (0.1 % to 1 %) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
QTcF &lt; 500 msek) pri bolnikih, zdravljenih z olanzapinom, redka (od 0,1 % do 1 %), brez pomembnih razlik v spremljajočih srčnih dogodkih v primerjavi z bolniki, zdravljenimi s placebom.
≥ 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF &lt; 500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
QTcF &lt; 500 msek) pri bolnikih, zdravljenih z olanzapinom, redka (od 0,1 % do 1 %), brez pomembnih razlik v spremljajočih srčnih dogodkih v primerjavi z bolniki, zdravljenimi s placebom.
≥ 6 x 106 cells/kg in ≤ 4 apheresis days with Mozobil and G-CSF (n=112; 75.7%) than with placebo and G-CSF (n=79; 51.3%), p &lt; 0.001; statistically significantly more patients achieved ≥ 2 x 106 cells/kg in ≤ 4 apheresis days with Mozobil and G-CSF (n=141; 95.3%) than with placebo and G-CSF (n=136; 88.3%), p=0.031.
51,3 %), p &lt; 0,001; statistično značilno več bolnikov je doseglo ≥ 2 x 106 celic/kg v ≤ 4 dneh afereze z zdravilom Mozobil in G-CSF (n = 141; 95,3 %) kot s placebom in G-CSF (n = 136; 88,3 %), p &lt; 0,031.
≥ 8 % to &lt; 9.0 %
≥ 8 % do &lt; 9,0
≥ Grade 3 neutropenia with fever, Grade 4 neutropenia lasting more than 7 days, a platelet count &lt; 10,000 cells/μL
nevtropenija z zvečano telesno temperaturo stopnje ≥ 3, nevtropenija 4. stopnje, ki traja več kot 7 dni, število
≥ Grade 3 neutropenia with fever, Grade 4 neutropenia lasting more than 7 days, a platelet count &lt; 10,000 cells/μL
nevtropenija z zvečano telesno temperaturo stopnje ≥ 3, nevtropenija 4. stopnje, ki traja več kot 7 dni, število trombocitov &lt; 10.000 celic/μl
≥1/1,000 to &lt; 1/100
≥ 1/1000 do &lt; 1/100
≥1/1,000 to &lt; 1/100
≥1/1.000 do &lt; 1/100
≥1/10, common ≥1/100 to &lt; 1/10, uncommon ≥1/1,000 to &lt; 1/100, rare ≥1/10,000 to &lt; 1/1,000 and not known (frequency cannot be estimated from available data).
≥ 1/100 do &lt; 1/10), občasni (od ≥ 1/1000 do &lt; 1/100), redki (od ≥ 1/10.000 do &lt; 1/1000) in neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
≥1/10,000 to &lt; 1/1,000
≥ 1/10.000 do &lt; 1/1000
≥1/100 to &lt; 1/10
≥ 1/100 do &lt; 1/10
≥1/100 to &lt; 1/10
≥1/100 do &lt; 1/10
≥1/100 to &lt; 1/10 of patients treated with mycophenolate mofetil in the controlled clinical trials of renal (2°g data), cardiac and hepatic transplant patients are listed in the following table.
1/100 do &lt; 1/10 bolnikov, zdravljenih z mofetilmikofenolatom v nadziranih kliničnih preskušanjih bolnikov z ledvičnim (podatki za 2 g), srčnim ali jetrnim presadkom, so našteti v spodnji preglednici.
≥1/100 to &lt; 1/10; uncommon: ≥1/1,000 to &lt; 1/100; rare: ≥1/10,000 to &lt; 1/1,000; very rare: &lt; 1/10,000).
≥ 1/10; pogosti: ≥ 1/100 do &lt; 1/10; občasni: ≥ 1/1.000 do &lt; 1/100; redki: ≥ 1/10.000 do &lt; 1/1.000; zelo redki: &lt; 1/10.000).
≥10% to &lt; 50%a
≥ 10 % do &lt; 50 %a
≥2 relapses in the prior year and 30% had previously received other approved MS treatments.
&gt; 3,5, 32 % jih je imelo ≥ 2 recidiva v predhodnem letu in 30 % se jih je predhodno zdravilo z drugimi odobrenimi oblikami zdravljenja MS.
≥30 CLcr &lt; 50 4 mg (4 ml of concentrate for solution for infusion)
≥30 CLcr &lt; 50 4 mg (4 ml koncentrata za raztopino za infundiranje)
≥35 years
&lt; 35 let
≥3x and &lt; 5x Upper Limit of Normal (ULN)
≥ 3-krat in &lt; 5-krat zgornja meja normalne vrednosti (ULN – Upper Limit of Normal)
≥50 CLcr &lt; 80 6 mg (6 ml of concentrate for solution for infusion)
≥50 CLcr &lt; 80 6 mg (6 ml koncentrata za raztopino za infundiranje)
≥7 mg Fe/g dw
koraki za zviševanje ≥7 mg Fe/g suhe
 p &lt; 0.0001  p &lt; 0.001  p &lt; 0.01  p &lt; 0.05 compared to placebo (1) BOD: burden of disease: total lesion volume (T2 and T1 hypointense) in ml
 p &lt; 0,0001  p &lt; 0,001  p &lt; 0,01  p &lt; 0,05 v primerjavi s placebom (1) BB: breme bolezni: skupen volumen lezij (T2 in T1 hipointenzivno) v ml
 15 (functionally anephric, requiring intermittent haemodialysis)*
&lt; 15 (funkcionalno anefričen, zahteva intermitentno hemodializo)
1/10), uncommon (1/1000 to 1/100), rare (1/10,000 to &lt; 1/1000) and not known (frequency cannot be estimated from the available data).
&lt; 1/10), občasni ( 1/1.000 do &lt; 1/100), redki ( 1/10.000 do &lt; 1/1.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
1/100), rare (1/10,000 to 1/1,000), very rare (1/10,000) and not known (cannot be estimated from the available data).
&lt; 1/100); redki (1/10.000 do &lt; 1/1.000); zelo redki ( &lt; 1/10.000) in neznani (iz razpoložljivih podatkov jih ni možno oceniti).
1/1000); and very rare (1/10,000), not known (cannot be estimated from the available data).
&lt; 1/1.000) zelo redki ( &lt; 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
 Significantly associated with Betaferon treatment for patients with first event suggestive of MS, p &lt; 0.05
 pomembno povezano z zdravljenjem z zdravilom Betaferon pri bolnikih s prvim kliničnim dogodkom, ki kaže na MS, p &lt; 0,05
 Significantly associated with Extavia treatment for patients with first event suggestive of MS, p
 pomembno povezano z zdravljenjem z zdravilom Extavia pri bolnikih s prvim dogodkom, ki kaže na MS, p &lt; 0,05
 &lt; 0; 82.2
IZ: -386,2; 99,6).
 0.5 and &lt; 1.5 x 109/l
 0,5 in &lt; 1,5 x 109/l
 10 and &lt; 100 x 109/l
 10 in &lt; 100 x 109/l
 30 - &lt; 50 mL/min) renal impairment, the pharmacokinetics of a single 200 mg dose of avanafil were not altered.
&lt; 50 ml/min) okvaro ledvic se farmakokinetika enkratnega odmerka 200 mg avanafila ni spremenila.
1/1,000 to &lt; 1/100, rare 1/10,000 to &lt; 1/1,000, very rare &lt; 1/10,000)) of Extavia use.
1/10.000 do &lt; 1/1.000, zelo redki &lt; 1/10.000)).
1/1,000 to &lt; 1/100; rare: 1/10,000 to &lt; 1/1,000; very rare: &lt; 1/10,000), not known (cannot be estimated from the available data).
≥ 1/1.000 do &lt; 1/100; redki: ≥ 1/10.000 do &lt; 1/1.000; zelo redki: &lt; 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
1/1,000 to &lt; 1/100; rare: 1/10,000 to &lt; 1/1,000; very rare: &lt; 1/10,000), not known (cannot be estimated from the available data).
≥ 1/1.000 do &lt; 1/100; redki: ≥ 1/10.000 do, &lt; 1/1.000; zelo redki: &lt; 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
1/100 to &lt; 1/10; uncommon:  1/1,000 to ≤ 1/100; rare:  1/10,000 to ≤1/1,000; very rare ≤1/10,000) and system organ class by decreasing order of seriousness; these adverse reactions should be interpreted within the surgical and medical context.
 1/10; pogosti  1/100 do &lt; 1/10; občasni  1/1.000 do &lt; 1/100; redki  1/10.000 do &lt; 1/1.000; zelo redki ≤ 1/10.000) in organski sistem v padajočem vrstnem redu po resnosti; te neželene učinke moramo interpretirati v povezavi s kirurškim in internističnim posegom.
1/100 to &lt; 1/10 of patients treated with mycophenolate mofetil in the controlled clinical trials of renal (2°g data), cardiac and hepatic transplant patients are listed in the following table.
1/100 do &lt; 1/10 bolnikov, zdravljenih z mofetilmikofenolatom v nadziranih kliničnih preskušanjih bolnikov z ledvičnim (podatki za 2 g), srčnim ali jetrnim presadkom, so našteti v spodnji preglednici.
4-point reduction in the SELENA-SLEDAI score, and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores, and no worsening ( &gt; 0.30 point increase) in Physician’s Global Assessment score (PGA)
zmanjšanje rezultata SELENA-SLEDAI za  4 točke in brez novih točk organskega področja BILAG (British Isles Lupus Assessment Group) A ali 2 novi točki organskega področja BILAG B ter brez poslabšanja (povečanja za &gt; 0,30 točke) rezultata PGA (Physician's Global Assessment)
� Check the label to make sure it is the right type of insulin
preverite nalepko, da se boste prepricali, ali imate pravo vrsto insulina; dezinficirajte gumijasto membrano z medicinskim zložencem.
� If you feel a hypo coming on (a hypo is short for a hypoglycaemic reaction and is a symptom of low blood sugar).
Možni neželeni ucinki; ce cutite, da se pojavlja hipa (hipa je okrajšava za hipoglikemicno reakcijo in pomeni simptome nizkega sladkorja v krvi).
"8th Meeting of People Experiencing Poverty", Brussels, 15 May 2009 ( 10558/09 )
"8. srečanje ljudi, ki se spopadajo z revščino", Bruselj, 15. maj 2009 ( 10558/09 )
"Alternative operators must be given sufficient time to climb the investment ladder and roll out their own networks.
„ Alternativnim operaterjem je treba dati dovolj časa, da dobijo sredstva za naložbe in razvijejo lastna omrežja.
"and so I urge the 27 Member States and six partner countries to reach a multilateral agreement enabling the European Grouping of Territorial Cooperation (EGTC) to be used in Armenia, Azerbaijan, Belarus, Georgia, Moldova and Ukraine as it is in the EU.
"Zato pozivam 27 držav članic in 6 partnerskih držav k sklenitvi večstranskega sporazuma, ki bo tako kot v Evropski uniji tudi v Armeniji, Azerbajdžanu, Belorusiji, Gruziji, Moldaviji in Ukrajini omogočal uporabo Evropskega združenja za teritorialno sodelovanje (EZTS).
"Care and Protection of Senior Citizens - the dignity and risks of the elderly", Prague, 25-26 May 2009 ( 10561/09 )
"Oskrba in varstvo starejših oseb – dostojanstvo in tveganja pri starejših", Praga, 25. in 26. maj 2009 ( 10561/09 )
"Flexicurity", Prague, 25-26 March 2009 ( 10560/09 )
"Prožna varnost", Praga, 25. in 26. marec 2009 ( 10560/09 )
"Following the exchange of views at the informal JHA ministers meeting held on 15 January 2009 in Prague, and referring to the Note of the Presidency as set out in document , the Council,
"Na podlagi izmenjave mnenj na neformalnem srečanju ministrov za PNZ 15. januarja 2009 v Pragi in ob upoštevanju gradiva, ki ga je predsedstvo predložilo v dokumentu , Svet
"Marking the fifth anniversary of the largest recent enlargement the Council WELCOMES the Commission report called “Five years of an enlarged EU: Economic achievements and challenges” and agrees with its overall assessment.
"Ob peti obletnici nedavne največje širitve EU Svet POZDRAVLJA poročilo Komisije "Pet let razširjene EU – gospodarski dosežki in izzivi" in se strinja s splošno oceno iz poročila.
"New Ways to overcome Gender Stereotypes", Prague, 27 May 2009 ( 10562/09 )
"Novi načini premagovanja spolnih stereotipov", Praga, 27. maj 2009 ( 10562/09 )
"Social Services", Prague, 22-23 April 2009 ( 10559/09 )
"Socialnovarstvene storitve", Praga, 22.–23. april 2009 ( 10559/09 )
"Who will feed the world?" – conference in Brussels on 3 July 2008.
Konferenca z naslovom " ?", Bruselj, 3. julij 2008
(1) Guided by internationally agreed principles, Member States have taken strong and decisive actions to stimulate their economies, provide liquidity, strengthen the capital of financial institutions, protect savings and deposits, address regulatory deficiencies and unfreeze credit markets.
(1) Izhajajoč iz mednarodno dogovorjenih načel so države članice sprejele učinkovite in odločne ukrepe za spodbujanje gospodarstev, zagotovitev likvidnosti, utrditev kapitala finančnih institucij, zaščito prihrankov in vlog, odpravo regulativnih pomanjkljivosti ter odmrznitev kreditnih trgov.
(1) STRESSES the importance of UNFF-8 for strengthening the integration of environmental aspects into forest policy dialogue and sustainable forest management at all levels;
(1) POUDARJA pomen UNFF-8 za večjo vključenost okoljskih vidikov v dialog o gozdarski politiki in trajnostno upravljanje gozdov na vseh ravneh.
(1) Without prejudice to ANNEX III of directive 2006/112/EC services in Annex IV of directive 2006/112/EC
(1) storitve iz priloge IV k direktivi 2006/112/ES – brez poseganja v PRILOGO III k tej direktivi
(1) Reduction of energy consumption, water consumption and CO 2 emissions from buildings :
(1) Zmanjšanje porabe energije in vode v stavbah ter emisij CO 2 iz njih :
(10) RECOGNISES that further work is needed to increase synergies, cooperation and coordination and consistency in financing SFM at all levels (global, regional and national) and therefore CONSIDERS that the future financing arrangement should facilitate and improve access to and use of various existing and emerging financial instruments, building upon the collaborative work of the CPF members, with a view to developing a dedicated service that improves coordination and coherence between those instruments;
(10) PRIZNAVA, da je potrebno nadaljnje delo za večjo sinergijo, boljše sodelovanje in usklajevanje ter doslednost pri financiranju trajnostnega upravljanja gozdov na vseh ravneh (svetovni, regionalni in državni), in zato MENI, da bi morala prihodnja ureditev financiranja olajšati in izboljšati dostopnost raznih obstoječih in novih finančnih instrumentov ter njihovo uporabo, k čemur bi moralo prispevati kooperativno delo članov Partnerstva za gozdove pri razvijanju namenskih storitev, ki izboljšujejo usklajenost in skladnost teh instrumentov.
(11) EMPHASISES, in this respect, the need to increase the role of the CPF, inter alia through continuing the activities of the advisory group on finance and further developing the CPF Sourcebook on Funding for SFM, as well as the need to increase the role of the National Forest Programme (NFP) Facility and other international and regional entities in encouraging and assisting countries to strengthen their capacity to develop national forest financing strategies within the framework of national forest programmes;
(11) POUDARJA, da je treba pri tem povečati vlogo Partnerstva za gozdove, med drugim z nadaljnjimi dejavnostmi svetovalne skupine za finance in razvojem vodnika Partnerstva za gozdove o financiranju trajnostnega upravljanja gozdov, pa tudi vlogo sklada za nacionalne programe za gozdove (National Forest Programme Facility) ter drugih mednarodnih in regionalnih subjektov pri spodbujanju in podpiranju držav pri večanju zmogljivosti za razvoj nacionalnih strategij za financiranje naložb v gozdove v okviru nacionalnih programov za gozdove.
(12) NOTES that various existing and emerging financial instruments, such as the World Bank's Forest Investment Programme (FIP), as well as possible financial arrangements that may be part of the post-2012 climate agreement, may provide new and additional resources to support efforts towards the implementation of the NLBI and SFM;
(12) UGOTAVLJA, da lahko dodatna sredstva za prizadevanja za izvajanje NLBI in trajnostno upravljanje gozdov zagotovijo razni obstoječi in novi finančni instrumenti, kot so program Svetovne banke za naložbe v gozdove ter morebitne ureditve financiranja iz podnebnega dogovora po letu 2012.
(13) UNDERLINES that Official Development Assistance (ODA) is most effective when delivered in accordance with the Paris Declaration on Aid Effectiveness in support of the objectives set in recipient countries' Poverty Reduction Strategies (PRS) and other national development strategies, RECOGNISES self-determination as a core element of PRS and ENCOURAGES recipient countries to foster the development and implementation of national forest financing strategies;
(13) POUDARJA, da je uradna razvojna pomoč (URP) najučinkovitejša, kadar se daje v skladu s Pariško deklaracijo o učinkovitosti pomoči v podporo ciljem iz strategij držav prejemnic za zmanjšanje revščine in drugih nacionalnih razvojnih strategij, PRIZNAVA, da je samostojno določanje osnovni element strategij za zmanjšanje revščine, ter SPODBUJA države prejemnice, da pospešijo razvoj in izvajanje nacionalnih strategij za financiranje naložb v gozdove.
(14) TAKES THE VIEW that public policies, including financing, should contribute to improving the enabling environment for private sector investments in SFM by addressing, inter alia, market, policy and governance failures, forest law enforcement and deficits in information, training and institutional capacity;
(14) MENI, da bi morale javne politike, tudi financiranja, prispevati k ugodnejšemu okolju za naložbe zasebnega sektorja v trajnostno upravljanje gozdov ter se v ta namen med drugim posvetiti slabostim trga, politik in upravljanja, uveljavljanju zakonodaje na področju gozdov in pomanjkljivostim pri obveščanju, usposabljanju in zagotavljanju institucionalne usposobljenosti.